JP2014510152A5 - - Google Patents

Download PDF

Info

Publication number
JP2014510152A5
JP2014510152A5 JP2014504014A JP2014504014A JP2014510152A5 JP 2014510152 A5 JP2014510152 A5 JP 2014510152A5 JP 2014504014 A JP2014504014 A JP 2014504014A JP 2014504014 A JP2014504014 A JP 2014504014A JP 2014510152 A5 JP2014510152 A5 JP 2014510152A5
Authority
JP
Japan
Prior art keywords
formulation
viscosity
acetate
reduced
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014504014A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510152A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/032464 external-priority patent/WO2012141978A2/en
Publication of JP2014510152A publication Critical patent/JP2014510152A/ja
Publication of JP2014510152A5 publication Critical patent/JP2014510152A5/ja
Pending legal-status Critical Current

Links

JP2014504014A 2011-04-07 2012-04-06 粘度が低減された処方物 Pending JP2014510152A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161473123P 2011-04-07 2011-04-07
US61/473,123 2011-04-07
PCT/US2012/032464 WO2012141978A2 (en) 2011-04-07 2012-04-06 Formulations with reduced viscosity

Publications (2)

Publication Number Publication Date
JP2014510152A JP2014510152A (ja) 2014-04-24
JP2014510152A5 true JP2014510152A5 (enExample) 2015-05-21

Family

ID=47009919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014504014A Pending JP2014510152A (ja) 2011-04-07 2012-04-06 粘度が低減された処方物

Country Status (12)

Country Link
US (1) US20140044727A1 (enExample)
EP (1) EP2694708A4 (enExample)
JP (1) JP2014510152A (enExample)
KR (1) KR20140066124A (enExample)
CN (1) CN103582724A (enExample)
AU (1) AU2012243126A1 (enExample)
BR (1) BR112013025845A2 (enExample)
CA (1) CA2832560A1 (enExample)
EA (1) EA201391489A1 (enExample)
IL (1) IL228626A0 (enExample)
SG (1) SG193964A1 (enExample)
WO (1) WO2012141978A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2523688T1 (en) * 2010-01-15 2018-03-30 Kirin-Amgen, Inc. Formulation of antibodies and therapeutic regimes
BR112013025866A2 (pt) * 2011-04-07 2016-12-20 Glaxosmithkline Llc formulações com viscosidade reduzida
CN104520326A (zh) * 2012-06-21 2015-04-15 Ucb医药有限公司 药物制剂
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
SG11201702614SA (en) 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
ES3053874T3 (en) 2015-08-24 2026-01-27 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions
CN105733250B (zh) * 2016-05-04 2017-12-26 山东省药学科学院 一种交联聚谷氨酸悬浮液及其制备方法与应用
US10980881B2 (en) * 2017-01-11 2021-04-20 Celltrion Inc. Stable liquid formula having an anti-TNFalpha antibody, acetate buffer and glycine
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
PL3615066T3 (pl) * 2017-04-28 2024-04-29 Amgen Inc. Formulacje ludzkich przeciwciał anty-RANKL i sposoby ich zastosowania
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
CN110913887A (zh) 2017-06-06 2020-03-24 葛兰素史克有限责任公司 用于儿科患者的生物药物组合物和方法
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
MX2021004356A (es) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
MA54089A (fr) 2018-10-31 2022-02-09 Merck Sharp & Dohme Anticorps anti-pd-1 humain et procédés d'utilisation associés
JP7503056B6 (ja) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗lag3抗体および抗pd-1抗体の共-製剤
CN113660927A (zh) * 2019-04-23 2021-11-16 安进公司 使用低分子量聚乙烯吡咯烷酮(pvp)降低高浓度蛋白质配制品的黏度
GB202102258D0 (en) * 2021-02-17 2021-03-31 Arecor Ltd Novel composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60139944D1 (de) * 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US20050164929A1 (en) * 2000-11-06 2005-07-28 Lupine Logic, Inc. Methods of preventing and treating inflammatory bowel disease
CA2503871C (en) * 2002-11-01 2012-12-11 Glaxosmithkline Biologicals S.A. An immunogenic composition for generating an immune response against polio virus
WO2004060343A1 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Antibody-containing particles and compositions
KR101363777B1 (ko) * 2005-09-30 2014-02-14 메디뮨 리미티드 인터루킨―13 항체 조성물
JP5405122B2 (ja) * 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
JP5231810B2 (ja) * 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
US20100189721A1 (en) * 2007-07-06 2010-07-29 Smithkline Beecham Corporation Antibody formulations
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
AU2008304111B2 (en) * 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CN107095846A (zh) * 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 抗体配制剂
BR112012027828A2 (pt) * 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína

Similar Documents

Publication Publication Date Title
JP2014516924A5 (enExample)
RU2020123963A (ru) Стабилизированные препараты, содержащие антитела против ngf
JP2020537520A5 (enExample)
JP2019503349A5 (enExample)
JP2013543505A5 (enExample)
IL283424B2 (en) Stabilized formulations that include antibodies against the interleukin receptor (il-4r)
RU2016129624A (ru) Биспецифичные антитела против гаптена/против рецептора гематоэнцефалического барьера, их комплексы и их применение в качестве челноков гематоэнцефалического барьера
IL274846B2 (en) Formulation for anti-alpha 4 antibody in cell 7
RU2012131671A (ru) Способ полипептидной модификации для очистки полипептидных мультимеров
RU2013155695A (ru) Препараты антител против с-мет
NZ627859A (en) Stabilized formulations containing anti-ang2 antibodies
UA107211C2 (uk) Стабілізовані склади, які містять антитіла до рецептора інтерлейкіну 6 (il-6r)
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
MX363226B (es) Formulaciones de anticuerpos.
JP2013535190A5 (enExample)
JP2017515909A5 (enExample)
RU2015137685A (ru) Композиции антитела в низкой концентрации
JP2014522843A5 (enExample)
JP2014502955A5 (enExample)
EA200970880A1 (ru) Стабильные композиции на основе антител
RU2015123476A (ru) Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
AR088455A1 (es) Anticuerpos que antagonizan cd40l
HRP20192346T1 (hr) Molekule anti-lag-3 antitijela i njihove uporabe
JP2016539096A5 (enExample)
FI3355919T3 (fi) Yhdistelmähoito ihmisen kasvu- ja erilaistumistekijä 15:n (GDF-15) inhibiittoreita ja immuunitarkistuspiste-estäjiä käyttämällä